16 hours Ago By ABMN Staff
Analysts at Lifesci Capital initiated coverage on shares of Mereo BioPharma Group ( NASDAQ:MREO – Get Free Report ) in a research report issued on Tuesday, Benzinga reports. The firm set an “outperform” rating and a $10.00 price target on the stock.
Lifesci Capital’s target price would indicate a potential upside of 162.47% from the stock’s previous close. Several other analysts also recently weighed in on MREO.
Cantor Fitzgerald upgraded Mereo BioPharma Group to a “strong-buy” rating in a research report on Sunday, December 8th. Jefferies Financial Group assumed coverage on shares of Mereo BioPharma Group in a research note on Friday, December 6th. They issued a “buy” rating and a $7.
00 price target on the stock. Finally, Needham & Company LLC reiterated a “buy” rating and set a $7.00 price objective on shares of Mereo BioPharma Group in a research report on Tuesday, November 12th.
Four investment analysts have rated the stock with a buy rating and three have given a strong buy rating to the company’s stock. Based on data from MarketBeat, Mereo BioPharma Group currently has an average rating of “Buy” and a consensus price target of $7.83.
Get Our Latest Report on MREO Mereo BioPharma Group Stock Performance Institutional Investors Weigh In On Mereo BioPharma Group Several hedge funds have recently added to or reduced their stakes in MREO. Deerfield Management Company L.P.
Series C bought a new position in Mereo BioPharma Group during the 2nd quarter worth $24,158,000. Janus Henderson Group PLC grew its position in shares of Mereo BioPharma Group by 56.7% during the 3rd quarter.
Janus Henderson Group PLC now owns 12,345,866 shares of the company’s stock worth $50,865,000 after buying an additional 4,464,984 shares during the period. Frazier Life Sciences Management L.P.
acquired a new stake in Mereo BioPharma Group in the second quarter worth $15,845,000. Rubric Capital Management LP grew its stake in shares of Mereo BioPharma Group by 12.9% in the 2nd quarter.
Rubric Capital Management LP now owns 15,307,347 shares of the company’s stock valued at $55,106,000 after buying an additional 1,754,350 shares during the period. Finally, Perceptive Advisors LLC bought a new stake in Mereo BioPharma Group in the 2nd quarter valued at about $4,512,000. 62.
83% of the stock is currently owned by institutional investors and hedge funds. About Mereo BioPharma Group ( Get Free Report ) Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors.
Further Reading Receive News & Ratings for Mereo BioPharma Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mereo BioPharma Group and related companies with MarketBeat.com's FREE daily email newsletter ..
